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variable is per capita pharmaceutical and other medical non-
durable expenditures. Explanatory variables investigated include
per capita GDP (Gross Domestic Product), % of elderly popu-
lation (65+ years), % of population with higher education
(college+), school expectancy, calorie intake per capita per day,
alcohol consumption in liters per capita (age 15+), % of expen-
ditures on pharmaceuticals and other medical non-durables
ﬁnanced by the public sector, number of practicing physicians,
% of population with public health care coverage, number of
doctor consultations per capita and % urbanized. All monetary
values were converted into US dollars based on GDP purchasing
power parity. A log-linear (constant elasticity) regression model
was used. RESULTS: The ﬁnal model included 6 explanatory
variables with an adjusted R2 = 0.744. The White test was used
to correct heteroskedasticity. The natural log of GDP per capita
(b = 0.455, p = 0.003), percent of elderly population (b = 0.039,
p = 0.01), number of doctor consultations (b = 0.028, p = 0.008),
and calories intake (b = 0.0003, p = 0.002) had positive, statis-
tically signiﬁcant effects on pharmaceutical expenditures at á 
< 0.01. Percent of population with higher education (b = 0.012,
p = 0.22) and public ﬁnancing (b = -0.001, p = 0.43) were not
signiﬁcant. Alcohol consumption (another indicator of lifestyle
behaviors); number of physicians and public health care cover-
age (indicators of relative size of the health care system); urban-
ization (indicator of development); and school expectancy
(another indicator of educational development) did not con-
tribute to the model. CONCLUSIONS: OECD countries with
more wealth, more elderly people, more doctor consultations,
and more calorie intake tend to spend more on pharmaceuticals
and other medical non-durables. Size of the health care system
and ﬁnancing methods do not explain differences in pharma-
ceutical expenditures.
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OBJECTIVES: All approved pharmaceutical products in Korea
are available for reimbursement except some products on the
negative list. The aim of this study is to examine how many prod-
ucts are actually prescribed by doctors and to compare the 
prescribing patterns in inpatient and outpatient settings.
METHODS: Prescription data were obtained from the Korean
National Health Insurance claims database of April 2004 for all
the hospitals and clinics in Korea. The numbers of prescribed
products and ingredients were calculated along with the drug
expenditure incurred. RESULTS: In April 2004, 19,452 phar-
maceutical products (5120 ingredients) were on the list of reim-
bursable drug formulary. Among them 9423 products (3208
ingredients), 48.2% of the reimbursable products, were actually
prescribed for inpatients. For outpatients, 11,823 products
(3731 ingredients), 60.8% of reimbursable products, were pre-
scribed. Although more than 9000 pharmaceutical products
were prescribed by doctors, top quintile high-expenditure drugs
of 1885 took up 94% of total drug expenditure for inpatients,
whereas top quintile 2365 products did 91.5% for outpatients.
Also, top quintile high-expenditure ingredients of 632 accounted
for 93% of total drug expenditure for inpatients, whereas those
of 746 ingredients did 92% for outpatients. CONCLUSIONS:
Unlike in western societies, more products and ingredients were
prescribed for outpatients than for inpatients in Korea. This
study also showed that although various pharmaceutical prod-
ucts were prescribed, the top 20% (high-expenditure drugs) of
all products and ingredients took up the lion’s share of total drug
expenditure. It suggests that there is a need of introduction 
of positive list formulary system for the efﬁcient drug beneﬁt
management.
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OBJECTIVES: In Ukraine the government authorizes the State
program of maintenance of the population by medical products
for 2004–2010, which provides use of pharmacoeconomic analy-
sis methods. The State Formulary for pharmaceutical provision
are formed. METHODS: We have analyzed all available phar-
macoeconomic studies published in Ukraine for 1998–2004 to
assess methodological problems and potential for future use of
pharmacoeconomics in drug policy. RESULTS: We have estab-
lished, that the quantity of published pharmacoeconomic
researches has increased in 7.3 times. Methodological quality is
generally insufﬁcient. Cost-minimization is the preferred tech-
nique although differences in effectiveness are not properly
assessed. Few studies desribe costing and cost-effectiveness
methodologies. Modeling studies are weak due absence of epi-
demiological and economical database. Societal perspective is
rarely used—the health care perspective prevails. Little study
exist in Qol measurement and cost-utility techniques. Industry
use of pharmacoeconomics is mainly for supporting marketing
and sales. Physicians are increasingly receptive of pharmaco-
economic analysis, but little value on modeling approaches. We
develop methodical recommendations on use of pharmaco-
economic analysis methods in Ukraine, authorized by Ministry
of Health. We have conducted the analysis of consumption of
antidiabetic agents in the deﬁned daily doses. We published 
the circular “A Technique of pharmacoeconomical analysis 
‘cost-effectiveness’ for deﬁnition of need in medicinal tools in
Ukraine”. CONCLUSION: Pharmacoeconomics must improve
methodological standarts in Ukraine. This is a task for both 
government and industry with the purpose of creation of State
Formulary.
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OBJECTIVES: To investigate the quality and completeness of
economic models submitted by pharmaceutical manufacturers to
health plans under the Academy of Managed Care Pharmacy
(AMCP) Format for formulary submissions, and to compare eco-
nomic models of “me-too” versus drugs judged to have signiﬁ-
cant competitive edge. METHODS: We analyzed economic
models included in AMCP-Format dossiers submitted by phar-
maceutical companies to the pharmacy services staff of Premera
Blue Cross (Mountlake Terrace, WA, enrollment 1.5 million) in
2003. “Economic models” were deﬁned as mathematical simu-
lations that combined clinical and cost data to estimate the eco-
nomic value of a drug. We assessed models’ compliance with
criteria recommended by the Panel on Cost-Effectiveness in
Health and Medicine, including: justiﬁcation of model type;
statement of time horizon and discount rate; discussion and
reporting of productivity changes; separate reporting of resource
quantities from prices; comparison against relevant alternatives;
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reports of incremental results, sensitivity analysis, and mention
of caveats. Outright budget impact models were not evaluated.
RESULTS: Of 35 dossiers submitted during 2003, 27 (77%)
included economic models. Of these, model type was justiﬁed in
8 (29%); time horizon stated in 22 (82%); discount rate stated
in 5 (19%); relevance of productivity changes discussed in 1
(4%) but reported in none; resource quantities reported sepa-
rately in 3 (11%); relevant alternatives compared in 11 (41%);
incremental results reported in 5 (19%); some form of sensitiv-
ity analysis in 15 (56%); caveats to conclusions mentioned in 4
(15%).Models of me-too drugs were signiﬁcantly less likely to
report comparisons against relevant alternatives (OR = 0.08, p
= 0.011) or incremental results (OR = 0.07, p = 0.03). No other
signiﬁcant differences were found. CONCLUSIONS: Most
dossiers submitted to one health plan in 2003 under the AMCP
Format contained economic models. Models had low levels of
compliance with broadly accepted recommendations. Models of
me-too drugs may be particularly prone to bias.
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OBJECTIVE: To test the hypothesis that the corporate structure
of large health insurance companies affects formulary design. By
choosing what is solely at the discretion of pharmacy beneﬁt
managers (PBMs), their national formularies, as the dependent
variable, rather than the generic utilization rate, the need to
factor out extraneous demand factors was minimized.
METHODS: The 2004 published formularies of the following
three groups were examined: a) the national formularies of four
large independent PBMs; b) the formularies of six large insur-
ance companies that have contracted with these large PBMs to
managed their drug beneﬁt plans; and c) the formularies of 
four large insurance companies that manage PBM functions
internally. Three therapeutic classes—proton pump inhibitors, 
COX-2 inhibitors, and second generation antihistamines—were
selected on the basis of widespread claims of the existence of
lower cost generics that are therapeutic equivalents. The number
of brand name drugs selected for the “Tier 2” was tallied for
each formulary across the three selected therapeutic classes.
RESULTS: There was no signiﬁcant difference in the number 
of “Tier 2” brand name drugs in the selected therapeutic 
classes of formularies of the large insurance companies with 
differing corporate structures. However, there was signiﬁcant
drop off in the number of brands included in the national for-
mularies of the four large, independent PBMs and the number
of brands in the “Tier 2” of ﬁnal plan formularies chosen 
by their clients. CONCLUSION: Large insurance companies
relying on independent PBMs for formulary management take
an active role in the design process and neutralize the effect that
corporate structure has on the starting point of the design
process.
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OBJECTIVE: To determine and evaluate the rate at which
abstracts presented at the ISPOR International and European
Congress Meetings during 2000–2003 were published.
METHODS: All contributed research abstracts categorized in
the Mental Health area during the 2000–2003 ISPOR Interna-
tional and European annual conferences that were posted on the
ISPOR website were searched for possible publications stemming
from the abstract. Both PubMed and Medline search engines
were used. For each abstract, the on-line search was initiated
using the ﬁrst author’s name, and then keywords within the title.
If no match was found, the next author was searched in a similar
fashion, until all the authors listed on the abstract were evalu-
ated. Publications that were similar in title, methods, results and
conclusions were considered a match. RESULTS: A total of 287
mental health abstracts were included in the study. Fifty-four
publications were identiﬁed in a total of 34 different journals.
The Journal of Clinical Psychiatry (6/54 = 11.1%) had the most
publications. The publication rates for the ISPOR International
conference in the years 2000, 2001, 2002, and 2003 were
22.6%, 22.5%, 20.8%, and 14.5%, respectively. The overall
publication rate of ISPOR International mental health abstracts
was 19.3%. In comparison, the ISPOR European publication
rates of mental health abstracts presented from 2000 to 2003
were 42.1%, 37.9%, 10.7% and 10%, respectively. With an
overall publication rate of 23.6%, slightly higher than the ISPOR
international publication rate. CONCLUSION: Pooled data
from the European and International ISPOR meetings showed a
publication rate between 13.0 and 30.0%. The publication rate
was highest in 2000 with a rate of 30.0% followed by publica-
tion rate of 29% in 2001, 17.1% in 2002 and 13.0% in 2003.
This trend of greater publication rates in the earlier years is not
unexpected given the lag time between submission, acceptance
and publication.
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OBJECTIVES: Emergency department (ED) use and costs were
examined for care of non-emergency problems during a one year
period for a patient cohort noted to be “homeless”. METHODS:
Using 2001–2002 Massachusetts ED data, a patient cohort was
identiﬁed by personal identiﬁers and the “homeless” indicator.
Visit reason was determined using ICD-9 diagnosis and visit
status codes. A non-emergency visit was deﬁned by a status other
than “emergency” and/or diagnosis not indicating a life threat-
ening condition (e.g., myocardial infraction) or injury. An ED
visit proﬁle was established for each patient over a one-year
period by tracking all non-emergency ED visits for 12 months
for each patient. Cost estimates, reported in 2004 USD, include
accommodations and ancillaries. Charges were adjusted using 
a 0.55 cost-to-charge ratio and appropriate inﬂation indices.
RESULTS: Less than 1% of ED visits were noted to be for 
homeless persons; however, 58% of ED cases had “unknown”
recorded for homeless status. Of the 2452 ED patients recorded
as homeless, 1244 (51%) were treated for non-emergency prob-
lems (males = 69%, mean age = 43 years). On average, these
patients had 1.4 non-emergency ED visits during the year (range:
1–14). Reason for visit: chronic and other medical = 28%,
alcohol/drug related = 27%, psychiatric = 14%, routine
exam/dental/ENT/eye = 10%, musculoskeletal = 10%, infection
= 9%, OB/GYN = 2%. Mean ED visit was 4.8 hours (median:
